Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
27.8M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
23.2M
-
Shares change
-
+469K
-
Total reported value, excl. options
-
$325M
-
Value change
-
+$6.87M
-
Number of buys
-
31
-
Number of sells
-
-16
-
Price
-
$14.03
Significant Holders of Benitec Biopharma Inc. - Common Stock, par value $0.0001 (BNTC) as of Q3 2025
61 filings reported holding BNTC - Benitec Biopharma Inc. - Common Stock, par value $0.0001 as of Q3 2025.
Benitec Biopharma Inc. - Common Stock, par value $0.0001 (BNTC) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.2M shares
of 27.8M outstanding shares and own 83.26% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (9.88M shares), JANUS HENDERSON GROUP PLC (2.91M shares), FRANKLIN RESOURCES INC (2.59M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.97M shares), VANGUARD GROUP INC (992K shares), BlackRock, Inc. (946K shares), Nantahala Capital Management, LLC (838K shares), INFINITUM ASSET MANAGEMENT, LLC (500K shares), GEODE CAPITAL MANAGEMENT, LLC (439K shares), and SILVERARC CAPITAL MANAGEMENT, LLC (276K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.